Physician profile
Paul Rubinstein
NPI 1356518534
$8,460.99
in general payments reported to CMS, 2019-2025
14 companies · $22.69 in 2025
The $22.69 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $55.12 · 2021: $3,571 · 2022: $367 · 2023: $3,674 · 2024: $351 · 2025: $22.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,800 · Food and Beverage: $932 · Travel and Lodging: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,800.00 |
| Food and Beverage | $931.79 |
| Travel and Lodging | $315.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $7,802.33 | 2019-2023 | Adcetris |
| Exelixis INC. | $189.93 | 2022-2024 | Cabometyx |
| Pfizer INC. | $137.75 | 2024 | |
| Incyte Corporation | $136.31 | 2022-2024 | Monjuvi |
| Takeda Pharmaceuticals U.S.A., INC. | $47.49 | 2020-2023 | Ninlaro |
| Celgene Corporation | $39.36 | 2024-2025 | Reblozyl |
| Amgen INC. | $25.19 | 2020 | |
| Genentech USA, INC. | $23.52 | 2021 | |
| Merck Sharp & Dohme LLC | $21.24 | 2023 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $19.08 | 2023 | |
| Epizyme, INC. | $18.79 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Rubinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.